Molecular mediators of angiogenesis in bladder cancer

Cancer Research

Volumn 58, Issue 6, 1998, Pages 1298-1304

  Campbell, Steven C ^a   Volpert, Olga V ^a   Ivanovich, Marina ^a   Bouck, Noël P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; BASIC FIBROBLAST GROWTH FACTOR; NEUTRALIZING ANTIBODY; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT INTERLEUKIN 8; SCATTER FACTOR; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ANGIOGENESIS; ANTIBODY DETECTION; ANTIGEN BINDING; ARTICLE; BLADDER CARCINOGENESIS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR DYNAMICS; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SECRETION;

CELLS, CULTURED; DOWN-REGULATION; ENDOTHELIAL GROWTH FACTORS; FIBROBLAST GROWTH FACTOR 2; HUMANS; LYMPHOKINES; NEOVASCULARIZATION, PATHOLOGIC; THROMBOSPONDIN 1; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; UROTHELIUM; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032521539     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Wingo, P. A., Tong, T., and Bolden, S. Cancer statistics, 1995. CA Cancer J. Clin., 45: 8-30, 1995.
2. Kroft, S. H., and Oyasu, R. Urinary bladder cancer: mechanisms of development and progression. Lab. Invest., 71: 158-174, 1994.
3. Catalona, W. J. Urothelial tumors of the urinary tract. In: P. C. Walsh, A. B. Retik, T. A. Stamey, and E. D. Vaughn, Jr. (eds.), Campbell's Urology, pp. 1094-1158. Philadelphia, PA: W. B. Saunders Co., 1992.
4. Lerner, S. P., and Skinner, D. G. Radical cystectomy for bladder cancer. In: N. C. Vogelzing, P. T. Scardino, W. U. Shipley, and D. S. Coffey (eds.), Comprehensive Textbook of Genitourinary Oncology, pp. 442-463. Baltimore: Williams & Wilkens, 1996.
5. Loehrer, P. J., Einhorn, L. H., and Elson, P. J. A randomized comparison of cisplatin along or in combination with methotrexate, vinblastine, and doxorubicin, in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol., 10: 1066-1073, 1992.
6. Folkman, J. The role of angiogenesis in tumor growth. Cancer Biol., 3: 65-71, 1992.
7. Campbell, S. C. Update on angiogenesis research: relevance to urologic oncology. J. Urol., 158: 1663-1674, 1997.
8. Bochner, B. H., Cote, R. J., and Weidner, N. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J. Natl. Cancer Inst. (Bethesda), 87: 1603-1612, 1995.
9. Jaeger, T. M., Weidner, N., and Chew, K. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J. Urol., 754: 69-71, 1995.
10. Grossfeld, G. D., Ginsberg, D. A., and Stein, J. P. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J. Natl. Cancer Inst. (Bethesda), 89: 219-227, 1997.
11. Tanaka, Y., Kawamata, H., and Fujimoto, K. Angiogenesis inhibitor TNP-470 suppresses tumorigenesis in rat urinary bladder. J. Urol., 157: 683-688, 1997.
12. Bouck, N., Stellmach, V., and Hsu, S. How tumors become angiogenic. Adv. Cancer Res., 69: 135-174, 1996.
13. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
14. Volpert, O. V., Dameron, K. M., and Bouck, N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene, 14: 1495-1502, 1997.
15. Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., and Kerbel, R. S. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res., 55: 4575-4580, 1995.
16. Hsu, S. C., Volpert, O. V., Steck, P. A., Mikkelson, T., Polverini, P. J., Rao, S., Chou, P., and Bouck, N. Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res., 56: 5684-5691, 1996.
17. Olumi, A. F., Tsai, Y. C., and Nicholas, P. Allelic loss of chromosome 17p distinguishes high grade from low-grade transitional cell carcinomas of the bladder. Cancer Res., 50: 7081-7083, 1990.
18. Lipponen, P. K. Over-expression of P53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int. J. Cancer, 53: 365-370, 1993.
19. Sarkis, A. S., Dalbagni, G., and Cordon-Cardo, C. Nuclear overexpression of P53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl. Cancer Inst. (Bethesda), 85: 53-59, 1993.
20. Esrig, D., Elmajian, D., and Groshen, S. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med., 331: 1259-1264, 1994.
21. Cordon-Cardo, C., Wartinger, D., Petrylak, D., Dalbagni, G., Fair, W. R., Fuks, Z., and Reuter, V. E. Altered expression of retinoblastoma gene product: prognostic indicator in bladder cancer. J. Natl. Cancer Inst. (Bethesda), 84: 1251-1256, 1992.
22. Logothetis, C., Xu, H. J., and Ro, J. Y. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J. Natl. Cancer Inst. (Bethesda), 84: 1256-1261, 1992.
23. Chopin, D. K., Caruelle, J. P., and Columbel, M. Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J. Urol., 150: 1126-1130, 1993.
24. Nguyen, M., Watanabe, H., and Budson, A. E. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J. Natl. Cancer Inst. (Bethesda), 85: 241-242, 1993.
25. O'Brien, T., Cranston, D., Fuggle, S., Bicknell, R., and Harris, A. L. Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer. Cancer Res., 57: 136-140, 1997.
26. O'Brien, T., Cranston, D., and Fuggle, S. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res., 55: 510-513, 1995.
27. O'Brien, T. S., Fox, S. B., Dickenson, A. J., Turley, H., Westwood, M., Moghaddam, A., Gatter, K. C., Bicknell, R., and Harris, A. L. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res., 56: 4799-4804, 1996.
28. Joseph, A., Weiss, G. H., and Jin, L. Expression of scatter factor in human bladder carcinoma. J. Natl. Cancer Inst. (Bethesda), 87: 372-377, 1995.
29. Rosen, E. M., Joseph, A., Jin, L., Yao, Y., Chau, M. H. T., Fuchs, A., Gomella, L., Hastings, H., Goldberg, I. D., and Weiss, G. H. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder. J. Urol., 72-78: 1997.
30. O'Brien, T., Cranston, D., Fuggle, S., Bicknell, R., and Harris, A. L. The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res., 56: 2515-2518, 1996.
31. Andrawis, R. I., Contrino, J., Lindquist, R. R., Albertson, P. C., Manyak, M. J., and Kreutzer, D. L. Interleukin-8 expression and human bladder cancer: in situ and in vitro expression of IL-8 by human bladder cancer cells. J. Urol., 157: 28, 1997.
32. Eder, I. E., Stenzl, A., and Hobisch, A. Transforming growth factors-B1 and B2 in serum and urine from patients with bladder carcinoma. J. Urol., 156: 953-957, 1996.
33. Lokeshwar, V. B., Obek, C., Soloway, M. S., and Block, N. L. Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res., 57: 773-777, 1997.
34. Volpert, O. V., Tolsma, S. S., and Pellerin, S. Inhibition of angiogenesis by thrombospondin-1. Biochem. Biophys. Res. Commun., 217: 326-332, 1995.
35. Weinstat-Saslow, D. L., Zabrenetzky, V. S., VanHoutte, K., Frazier, W. A., Roberts, D. D., and Steeg, D. L. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res., 54: 6504-6511, 1994.
36. Sheibani, N., and Frazier, W. A. Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis. Proc. Natl. Acad. Sci. USA, 92: 6788-6792, 1995.
37. Volpert, O. V., Lawler, J., and Bouck, N. P. Ectopic and tumor derived thrombospondin inhibits the growth of peripheral metastases. In: A. Berns, T. Grodzicker, E. Harlow, D. Livingston, C. Prives, and B. Vogelstein (eds.), Cancer Genetics and Tumor Suppressor Genes, p. 124. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1996.
38. Moghaddam, A., Zhang, H. T., Fan, T. P. D., Hu, D. E., Lees, V. C., Turley, H., Fox, S. B., Gatter, K. C., Harris, A. L., and Bicknell, R. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc. Natl. Acad. Sci. USA, 92: 998-1002, 1995.
39. Prater, C. A., Plotkin, J., Jaye, D., and Frazier, W. A. The properdin-like type I repeats of human thrombospondin contain a cell attachment site. J. Cell Biol., 112: 1031-1040, 1991.
40. Good, D. J., Polverini, P. J., Rastinejad, F., Le Beau, M. M., Lemons, R. S., Frazier, W. A., and Bouck, N. P. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA, 87: 6624-6628, 1990.
41. Dixit, V. M., Grant, G. A., Santoro, S. A., and Frazier, W. A. Isolation and characterization of a heparin-binding domain from the amino terminus of platelet thrombospondin. J. Biol. Chem., 259: 10100-10105, 1997.
42. Johnson, M. D., Bryan, G. T., and Reznikoff, C. A. Serial cultivation of normal rat bladder epithelial cells in vitro. J. Urol., 133: 1076-1081, 1985.
43. Liebert, M., Wedemeyer, G., Cheng, J. H. C., Stein, J. A., McKeeves, P. E., Carey, T. E., Flint, A., Stepleroski, Z., Buschsbaun, D. J., Wahl, R. L., and Grossman, H. B. Comparison of antigen expression on normal urothelial cells in tissue section and tissue culture. J. Urol., 144: 1288-1292, 1990.
44. Polverini, P. J., Bouck, N. P., and Rastinejad, F. Assay and purification of naturally occurring inhibitor of angiogenesis. Methods Enzymol., 198: 440-450, 1991.
45. Pepper, M. S., Ferrara, N., Orci, L., and Montesano, R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem. Biophys. Res. Commun., 189: 824-831, 1992.
46. Goto, F., Goto, K., Weindel, K., and Folkman, J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab. Invest., 69: 508-517, 1993.
47. Bornstein, P. Thrombospondins: structure and regulation of expression. FASEB J., 6: 3290-3299, 1992.
48. Hugo, C., Pichler, R., Meek, R., Gordon, K., Kyriakides, T., Floege, J., Bornstein, P., Couser, W. G., and Johnson, R. J. Thrombospondin 1 is expressed by proliferating mesangial cells and is up-regulated by PDGF and bFGF in vivo. Kidney Int., 48: 1846-1856, 1995.
49. Cornali, E., Zietz, C., Benelli, R., Weninger, W., Masiello, L., Breier, G., Tschachler, E., Albini, A., and Sturzl, M. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am. J. Pathol., 149: 1851-1869, 1997.
50. Ferrara, N. Vascular endothelial growth factor. Eur. J. Cancer, 32A: 2413-2422, 1997.
51. Kuroda, M., Oka, T., Yamochi, T., Ohtsubo, K., Mori, S., Watanabe, T., Machinami, R., and Ohnishi, S. Colocalization of vascular endothelial growth factor (vascular permeability factor) and insulin in pancreatic islet cells. J. Clin. Endocrinol. Metab., 80: 3196-3200, 1995.
52. Berse, B., Brown, L. F., Van De Water, L., Dvorak, H. F., and Senger, D. R. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol. Biol. Cell, 3: 211-220, 1992.